Dosing for Two: How Pregnancy Rewrites the Rules of Medication Safety

For most adults, a stable prescription represents a carefully negotiated agreement between their body and a specific dose. That agreement, built through months or even years of monitoring and adjustment, can be upended almost immediately upon conception. Pregnancy does not simply add a second person to the equation — it fundamentally restructures the physiological environment in which every medication must operate.

The result is what clinicians sometimes refer to informally as the pregnancy dosing paradox: a dose that was once precisely calibrated to keep a patient healthy may become either dangerously potent or frustratingly ineffective the moment a pregnancy begins. For millions of American women who manage chronic conditions while pregnant — including hypertension, diabetes, epilepsy, thyroid disorders, and depression — navigating this paradox is not theoretical. It is an urgent, ongoing medical challenge.

What Pregnancy Actually Does to Your Body's Drug-Processing System

To understand why dosing changes during pregnancy, it helps to appreciate just how dramatically the body transforms. Blood plasma volume increases by as much as 50 percent over the course of a pregnancy. Cardiac output rises. The kidneys filter blood at a significantly accelerated rate — a phenomenon called increased glomerular filtration — which means water-soluble medications are cleared from the body far more quickly than they would be otherwise.

At the same time, elevated levels of progesterone alter the activity of liver enzymes responsible for breaking down many medications. Some of these enzymes become more active, metabolizing certain drugs faster and reducing their concentration in the bloodstream. Others slow down, allowing drugs to accumulate to higher-than-expected levels.

Gastric motility also decreases, slowing the rate at which oral medications are absorbed. And the placenta itself can metabolize some compounds before they even reach maternal circulation. Taken together, these changes mean that the same 100-milligram tablet a woman took confidently for two years before pregnancy may produce an entirely different plasma concentration once she is expecting.

The Trimester Factor: A Moving Target Across Nine Months

Complicating matters further is the fact that these physiological changes are not static. They evolve across the three trimesters, meaning that a dosing strategy appropriate at eight weeks may be inadequate — or excessive — by week twenty-eight.

During the first trimester, nausea and vomiting can interfere with medication absorption unpredictably. A patient managing hypothyroidism, for example, may struggle to absorb her levothyroxine consistently, leading to fluctuating thyroid hormone levels at precisely the time fetal neurological development is most sensitive.

By the second trimester, increased renal clearance is often at its most pronounced. Women taking lithium for bipolar disorder, for instance, may require dose increases during this period simply because their kidneys are eliminating the drug so efficiently that therapeutic blood levels become difficult to maintain. Conversely, as delivery approaches and certain physiological parameters shift again, that same elevated dose can become toxic in the postpartum period if not promptly adjusted.

Conditions That Demand Careful Dose Recalibration

Hypertension: Chronic high blood pressure during pregnancy — and the related condition of gestational hypertension — requires careful medication selection and dosing. Certain antihypertensives used routinely outside of pregnancy, including ACE inhibitors and angiotensin receptor blockers, are contraindicated due to fetal harm. Medications like labetalol, nifedipine, and methyldopa are generally preferred, but their dosing must be monitored closely as plasma volume shifts alter their distribution and clearance throughout gestation.

Thyroid Disorders: Women with hypothyroidism managed on levothyroxine almost universally require a dose increase during pregnancy — often by 25 to 50 percent — because rising estrogen levels increase thyroid-binding globulin, effectively reducing the amount of free, active thyroid hormone available. Providers typically begin monitoring thyroid-stimulating hormone levels more frequently once pregnancy is confirmed.

Depression and Anxiety: Selective serotonin reuptake inhibitors (SSRIs) represent one of the more nuanced dosing challenges in obstetric care. Increased plasma volume and accelerated hepatic metabolism during the second and third trimesters can meaningfully reduce SSRI concentrations, sometimes requiring dose adjustments upward to maintain therapeutic effect. Yet providers must simultaneously weigh the risks of neonatal adaptation syndrome in newborns exposed to SSRIs late in pregnancy. This is rarely a simple calculation.

Epilepsy: Anti-seizure medications present some of the highest-stakes dosing scenarios in pregnancy. Lamotrigine, widely used for epilepsy and bipolar disorder, is metabolized significantly faster during pregnancy due to enzyme induction — with clearance increasing by as much as 300 percent in some patients. Without proactive dose escalation and frequent serum level monitoring, breakthrough seizures become a real risk. Yet over-correction carries its own fetal exposure concerns.

Diabetes: Insulin requirements shift considerably across pregnancy. In the first trimester, insulin sensitivity often temporarily improves, raising the risk of hypoglycemia. By the second and third trimesters, placental hormones drive increasing insulin resistance, frequently requiring substantial dose increases. Women with pre-existing type 1 or type 2 diabetes must work closely with their care team to adjust dosing in real time.

Medications That Must Be Stopped Entirely

For some drugs, the conversation is not about recalibration — it is about cessation. Warfarin, isotretinoin, methotrexate, thalidomide derivatives, and several antiepileptic drugs such as valproate carry well-documented risks of severe fetal harm and are contraindicated during pregnancy. In these cases, providers must identify safer alternatives before conception occurs when possible, or transition patients promptly upon a confirmed pregnancy.

The challenge is that abrupt discontinuation carries its own risks. A patient who stops a medication managing a serious psychiatric condition without a bridging strategy may face a relapse that poses its own dangers to maternal and fetal health. This is why pre-conception medication planning — working with providers before pregnancy begins — is considered best practice for women managing chronic conditions.

A Patient Scenario Worth Considering

Consider a 32-year-old woman in Chicago managing both generalized anxiety disorder on an SSRI and mild hypothyroidism on levothyroxine who discovers she is eight weeks pregnant. Her psychiatrist and OB-GYN must now coordinate rapidly. Her levothyroxine dose will almost certainly need to increase. Her SSRI dose may need upward adjustment as pregnancy progresses, balanced against monitoring for neonatal effects near term. Neither medication can simply be left on autopilot. Both require more frequent lab work, more office visits, and a shared understanding between patient and provider about what to watch for.

This is not an unusual scenario in American obstetric care — it is increasingly the norm as more women enter pregnancy already managing one or more chronic conditions.

What Patients Should Do

If you are pregnant or planning to become pregnant and currently take any prescription or over-the-counter medication, the single most important step is an early, transparent conversation with your healthcare provider. Do not assume that a medication deemed safe before pregnancy remains safe — or effective at the same dose — once you are expecting.

Bring a complete list of every medication, supplement, and herbal product you take. Ask specifically whether your dose may need adjustment as pregnancy progresses, which trimester changes are most likely, and what warning signs should prompt you to call your provider between scheduled visits.

Pregnancy is not a reason to abandon necessary treatment. But it is an unambiguous reason to revisit every dosing decision with fresh eyes — and with a provider who understands the profound physiological complexity of caring for two patients at once.